ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)

Autor: Drgona, L., Gudiol, C., Lanini, S., Salzberger, B., Ippolito, G., Mikulska, M.
Zdroj: In Clinical Microbiology and Infection June 2018 24 Supplement 2:S83-S94
Databáze: ScienceDirect